Now Reading: Starbucks ends weight-loss drug cover for US employees
-
01
Starbucks ends weight-loss drug cover for US employees
Starbucks will stop covering GLP-1 weight-loss drugs under its employee health plans from October, the coffee chain has confirmed to Business Insider. The medicines will still be available for diabetes and other…
The Story in Brief
Starbucks will stop covering GLP-1 weight-loss drugs under its employee health plans from October, the coffee chain has confirmed to Business Insider. The medicines will still be available for diabetes and other conditions. The move reflects a sharp rise in employer spending on these drugs, which accounted for 11.4% of corporate health claims in 2025, up from 6.9% two years earlier.
Average health-benefit costs per employee rose 6% last year and are expected to climb another 6.7% in 2025, with GLP-1 usage a key driver. Other large US employers, including Allina Health and PwC, have also cut weight-loss coverage. But some firms are bucking the trend: Bank of America spends over $250 million a year on the drugs, calling it an investment in employee health.
The Indian Opinion
The easy narrative is that big companies are heartlessly slashing benefits. But the data shows soaring costs, GLP-1 drugs now eat up more than 11% of corporate health claims, that are unsustainable without restructuring. At the same time, Bank of America proves some employers see value. The real test is whether other firms follow Starbucks or find ways to cover these drugs without breaking the budget. What will the next big employer do? Their decision will tell us if this is a trend or an exception.
Source: timesofindia.indiatimes.com
This story was synthesised by AI from the source linked above.
